Biomarkers for Allogeneic HCT Outcomes
Allogeneic hematopoietic cell transplantation (HCT) remains the only curative therapy for many hematological malignant and non-malignant disorders. However, key obstacles to the success of HCT include graft-versus-host disease (GVHD) and disease relapse due to absence of graft-versus-tumor (GVT) eff...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-04-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.00673/full |
| _version_ | 1819199020728320000 |
|---|---|
| author | Djamilatou Adom Djamilatou Adom Djamilatou Adom Courtney Rowan Courtney Rowan Courtney Rowan Titilayo Adeniyan Titilayo Adeniyan Titilayo Adeniyan Jinfeng Yang Jinfeng Yang Jinfeng Yang Sophie Paczesny Sophie Paczesny Sophie Paczesny |
| author_facet | Djamilatou Adom Djamilatou Adom Djamilatou Adom Courtney Rowan Courtney Rowan Courtney Rowan Titilayo Adeniyan Titilayo Adeniyan Titilayo Adeniyan Jinfeng Yang Jinfeng Yang Jinfeng Yang Sophie Paczesny Sophie Paczesny Sophie Paczesny |
| author_sort | Djamilatou Adom |
| collection | DOAJ |
| description | Allogeneic hematopoietic cell transplantation (HCT) remains the only curative therapy for many hematological malignant and non-malignant disorders. However, key obstacles to the success of HCT include graft-versus-host disease (GVHD) and disease relapse due to absence of graft-versus-tumor (GVT) effect. Over the last decade, advances in “omics” technologies and systems biology analysis, have allowed for the discovery and validation of blood biomarkers that can be used as diagnostic test and prognostic test (that risk-stratify patients before disease occurrence) for acute and chronic GVHD and recently GVT. There are also predictive biomarkers that categorize patients based on their likely to respond to therapy. Newer mathematical analysis such as machine learning is able to identify different predictors of GVHD using clinical characteristics pre-transplant and possibly in the future combined with other biomarkers. Biomarkers are not only useful to identify patients with higher risk of disease progression, but also help guide treatment decisions and/or provide a basis for specific therapeutic interventions. This review summarizes biomarkers definition, omics technologies, acute, chronic GVHD and GVT biomarkers currently used in clinic or with potential as targets for existing or new drugs focusing on novel published work. |
| first_indexed | 2024-12-23T03:09:42Z |
| format | Article |
| id | doaj.art-b7fdabf971f845e4b721f6432b9da100 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-23T03:09:42Z |
| publishDate | 2020-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-b7fdabf971f845e4b721f6432b9da1002022-12-21T18:02:16ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-04-011110.3389/fimmu.2020.00673531902Biomarkers for Allogeneic HCT OutcomesDjamilatou Adom0Djamilatou Adom1Djamilatou Adom2Courtney Rowan3Courtney Rowan4Courtney Rowan5Titilayo Adeniyan6Titilayo Adeniyan7Titilayo Adeniyan8Jinfeng Yang9Jinfeng Yang10Jinfeng Yang11Sophie Paczesny12Sophie Paczesny13Sophie Paczesny14Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, United StatesDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, United StatesMelvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, United StatesDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, United StatesDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, United StatesMelvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, United StatesDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, United StatesDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, United StatesMelvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, United StatesDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, United StatesDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, United StatesMelvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, United StatesDepartment of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, United StatesDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN, United StatesMelvin and Bren Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, United StatesAllogeneic hematopoietic cell transplantation (HCT) remains the only curative therapy for many hematological malignant and non-malignant disorders. However, key obstacles to the success of HCT include graft-versus-host disease (GVHD) and disease relapse due to absence of graft-versus-tumor (GVT) effect. Over the last decade, advances in “omics” technologies and systems biology analysis, have allowed for the discovery and validation of blood biomarkers that can be used as diagnostic test and prognostic test (that risk-stratify patients before disease occurrence) for acute and chronic GVHD and recently GVT. There are also predictive biomarkers that categorize patients based on their likely to respond to therapy. Newer mathematical analysis such as machine learning is able to identify different predictors of GVHD using clinical characteristics pre-transplant and possibly in the future combined with other biomarkers. Biomarkers are not only useful to identify patients with higher risk of disease progression, but also help guide treatment decisions and/or provide a basis for specific therapeutic interventions. This review summarizes biomarkers definition, omics technologies, acute, chronic GVHD and GVT biomarkers currently used in clinic or with potential as targets for existing or new drugs focusing on novel published work.https://www.frontiersin.org/article/10.3389/fimmu.2020.00673/fullbiomarkersgraft-versus-host diseasegraft-versus-tumorhematopoietic cell transplantationproteomics |
| spellingShingle | Djamilatou Adom Djamilatou Adom Djamilatou Adom Courtney Rowan Courtney Rowan Courtney Rowan Titilayo Adeniyan Titilayo Adeniyan Titilayo Adeniyan Jinfeng Yang Jinfeng Yang Jinfeng Yang Sophie Paczesny Sophie Paczesny Sophie Paczesny Biomarkers for Allogeneic HCT Outcomes Frontiers in Immunology biomarkers graft-versus-host disease graft-versus-tumor hematopoietic cell transplantation proteomics |
| title | Biomarkers for Allogeneic HCT Outcomes |
| title_full | Biomarkers for Allogeneic HCT Outcomes |
| title_fullStr | Biomarkers for Allogeneic HCT Outcomes |
| title_full_unstemmed | Biomarkers for Allogeneic HCT Outcomes |
| title_short | Biomarkers for Allogeneic HCT Outcomes |
| title_sort | biomarkers for allogeneic hct outcomes |
| topic | biomarkers graft-versus-host disease graft-versus-tumor hematopoietic cell transplantation proteomics |
| url | https://www.frontiersin.org/article/10.3389/fimmu.2020.00673/full |
| work_keys_str_mv | AT djamilatouadom biomarkersforallogeneichctoutcomes AT djamilatouadom biomarkersforallogeneichctoutcomes AT djamilatouadom biomarkersforallogeneichctoutcomes AT courtneyrowan biomarkersforallogeneichctoutcomes AT courtneyrowan biomarkersforallogeneichctoutcomes AT courtneyrowan biomarkersforallogeneichctoutcomes AT titilayoadeniyan biomarkersforallogeneichctoutcomes AT titilayoadeniyan biomarkersforallogeneichctoutcomes AT titilayoadeniyan biomarkersforallogeneichctoutcomes AT jinfengyang biomarkersforallogeneichctoutcomes AT jinfengyang biomarkersforallogeneichctoutcomes AT jinfengyang biomarkersforallogeneichctoutcomes AT sophiepaczesny biomarkersforallogeneichctoutcomes AT sophiepaczesny biomarkersforallogeneichctoutcomes AT sophiepaczesny biomarkersforallogeneichctoutcomes |